ASH Publishes Guidelines for Stem Cell Transplantation for Sickle Cell Disease

Posted in :: 2022 Volume 1 :: Monday, March 7th, 2022

The American Society for Hematology (ASH) released its first guidelines for stem cell transplantation for sickle cell disease. The guidelines weigh the risks and benefits of transplantation compared to disease-modifying treatments or potentially curative therapy in development. The guidelines are published in American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation (Kanter, et al. Blood Adv . 2021;doi:10.1182/bloodadvances.2021004394C).

Key recommendations in the guidelines include:

  1. HSCT should be considered the standard of care for patients who have had or have a high risk for stroke, as well as for all patients with neurologic injury who have a matched-related sibling donor.
  2. Patients with frequent pain and those with recurrent episodes of acute chest syndrome should use related matched allogeneic transplantation rather than standard of care.
  3. Patients with an indication for HSCT who lack a matched sibling donor should use transplants from alternative donors in the context of a clinical trial.

Read the guidelines